Red Flags, Pitfalls, and Cautions in Y90 Radiotherapy

Sergio Klimkowski, Jennifer C. Baker, Daniel B. Brown

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Radioembolization with yttrium-90 (Y90)microspheres is increasingly used to palliate patients with liver-dominant malignancy. With appropriate patient selection, this outpatient treatment is efficacious with limited toxicity profile. This article reviews common scenarios that can present in daily practice including evaluation of liver functions, evaluation of previous therapies, integrating Y90 into ongoing systemic therapy, determining performance status, and considering retreatment for patients who have already undergone Y90 who have hepatic dominant progression. Finally, we address the importance of evaluating tumors in potential watershed zones to maximize treatment response by using c-arm computed tomography. Many of these potential variables can overlap in an individual patient. By considering these factors individually, the consulting Interventional Radiologist can present a thorough treatment plan with a full description of expected outcomes and toxicities to clinic patients.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalTechniques in Vascular and Interventional Radiology
Issue number2
StatePublished - Jun 2019
Externally publishedYes


  • brachytherapy
  • liver cancer
  • liver metastases
  • radioembolization

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Red Flags, Pitfalls, and Cautions in Y90 Radiotherapy'. Together they form a unique fingerprint.

Cite this